Asunaprevir/beclabuvir/daclatasvir

Drug Profile

Asunaprevir/beclabuvir/daclatasvir

Alternative Names: Asunaprevir/daclatasvir/BMS 791325; BMS 791325/asunaprevir/daclatasvir; Daclatasvir/BMS 791325/asunaprevir; DCV 3DAA FDC; DCV 3DAA fixed dose combination; DCV-TRIO; DCV/ASV/BMS-791325

Latest Information Update: 08 Mar 2017

Price : $50

At a glance

  • Originator Bristol-Myers Squibb
  • Class Amides; Azabicyclo compounds; Benzazepines; Biphenyl compounds; Carbamates; Cyclohexanes; Cyclopropanes; Heterocyclic compounds with 4 or more rings; Imidazoles; Indoles; Isoquinolines; Organic bridged compounds; Phenyl ethers; Piperazines; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus NS3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 20 Feb 2017 Bristol-Myers Squibb initiates enrolment in an observational, postmarketing commitment study for Hepatitis C in Japan (NCT03071133)
  • 12 Feb 2016 Preregistration for Hepatitis C in Japan (PO)
  • 01 Feb 2016 Bristol-Myers Squibb in collaboration with Southern California Institute for Research and Education completes the RHACE 1 trial in Hepatitis C (Treatment-naïve) in USA (NCT02098616)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top